Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Current Assets (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Current Assets readings, the most recent being $6.4 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 31.23% to $6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.4 million, a 31.23% decrease, with the full-year FY2025 number at $6.4 million, down 31.23% from a year prior.
  • Current Assets hit $6.4 million in Q4 2025 for Arcadia Biosciences, down from $8.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $56.6 million in Q1 2021 to a low of $6.4 million in Q4 2025.
  • Median Current Assets over the past 5 years was $21.7 million (2023), compared with a mean of $23.2 million.
  • Biggest five-year swings in Current Assets: soared 138.29% in 2021 and later tumbled 57.21% in 2024.
  • Arcadia Biosciences' Current Assets stood at $35.4 million in 2021, then dropped by 28.23% to $25.4 million in 2022, then plummeted by 41.05% to $15.0 million in 2023, then plummeted by 38.27% to $9.2 million in 2024, then plummeted by 31.23% to $6.4 million in 2025.
  • The last three reported values for Current Assets were $6.4 million (Q4 2025), $8.4 million (Q3 2025), and $7.6 million (Q2 2025) per Business Quant data.